Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Eton Pharmaceuticals (ETON), BioNTech SE (BNTX) and CareDx (CDNA)

Tipranks - Tipranks - Fri Apr 17, 9:26AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Eton Pharmaceuticals (ETON), BioNTech SE (BNTX) and CareDx (CDNA).

Claim 30% Off TipRanks

Eton Pharmaceuticals (ETON)

Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Eton Pharmaceuticals today. The company’s shares closed last Thursday at $24.75.

According to TipRanks.com, Knickerbocker is a top 100 analyst with an average return of 35.8% and a 60.7% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Fennec Pharmaceuticals, and Xtant Medical Holdings. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eton Pharmaceuticals with a $41.50 average price target, a 59.4% upside from current levels. In a report released today, TipRanks – xAI also upgraded the stock to Buy with a $30.00 price target.

See today’s best-performing stocks on TipRanks >>

BioNTech SE (BNTX)

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on BioNTech SE. The company’s shares closed last Thursday at $99.55.

According to TipRanks.com, Ahmad is a 4-star analyst with an average return of 3.5% and a 53.7% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, KalVista Pharmaceuticals, and Bicara Therapeutics Inc. ;'>

Currently, the analyst consensus on BioNTech SE is a Strong Buy with an average price target of $137.27, representing a 37.6% upside. In a report issued on April 10, Morgan Stanley also maintained a Buy rating on the stock with a $126.00 price target.

CareDx (CDNA)

In a report released today, William Bonello from Craig-Hallum maintained a Hold rating on CareDx. The company’s shares closed last Thursday at $21.53.

According to TipRanks.com, Bonello is a 5-star analyst with an average return of 22.1% and a 55.7% success rate. Bonello covers the Healthcare sector, focusing on stocks such as Adaptive Biotechnologies, Strata Critical Medical, and GeneDx Holdings. ;'>

CareDx has an analyst consensus of Moderate Buy, with a price target consensus of $25.00, implying a 14.9% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Hold rating on the stock.

Read More on ETON:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).